North America Transparent Plastic Market Outlook, 2030

The menopause landscape in Europe has evolved from a little-noticed issue to a recognized public health priority as populations age and more women reach midlife. Menopause in Europe typically occurs between ages 49 and 52, with variations influenced by genetics, lifestyle, and socio-economic factors. According to the European Menopause and Andropause Society (EMAS), around 52% of European women aged 45–55 experience moderate to severe symptoms, including vasomotor disturbances, sleep disruption, and mood changes. Awareness levels vary across the continent, with Northern and Western Europe showing higher health literacy on menopause than parts of Eastern and Southern Europe. A 2023 EMAS survey found that 77.5% of European general practitioners rated their medical school or residency training on menopause as insufficient, highlighting a gap in provider preparedness. Gynecologists, endocrinologists, and general practitioners remain the primary point of care, supported by updated guidelines from EMAS, WHO, and the International Menopause Society, which shape therapy choices in the region. Lifestyle factors such as obesity, stress, and smoking rates in certain European populations correlate with symptom severity. Eurostat data shows that the 50–64 female population in Europe is projected to exceed 65 million by 2030, increasing demand for menopause care. Cultural openness, particularly in Scandinavian countries and parts of Western Europe, has supported higher treatment uptake, while NGOs like Menopause Matters and national advocacy groups continue to push for policy inclusion and better awareness. Digital health adoption is growing, with mobile symptom trackers and teleconsultations becoming integrated into menopause care pathways across urban and semi-urban regions.

According to the research report ""Europe Menopause Market Outlook, 2030,"" published by Bonafide Research, the Europe Menopause market is expected to reach a market size of more than USD 5.33 Billion by 2030. In Europe, treatment preferences are shifting toward a balanced mix of hormonal therapy and non-hormonal options, including dietary supplements and botanical extracts such as red clover and black cohosh. EMAS data indicates that nearly 48% of women seeking menopause care in Europe now prefer non-hormonal interventions, partly due to safety concerns following the Women’s Health Initiative findings and evolving patient preferences. The European Medicines Agency (EMA) plays a central role in regulating hormone replacement therapies, transdermal patches, and novel formulations, with recent approvals streamlining access in multiple member states. Telehealth use for menopause management has expanded rapidly, particularly in Germany, France, and the Nordic region, supported by national e-health strategies. Retail and online pharmacies remain vital distribution channels, ensuring accessibility across urban centers and rural areas. IQVIA reports that online pharmacy sales for menopause-related products in Europe rose by over 22% between 2021 and 2023, driven by convenience and post-pandemic behavior changes. R&D activity is increasing, with clinical trials focusing on selective estrogen receptor modulators, neurokinin 3 receptor antagonists, and plant-derived compounds. European startups are exploring personalized menopause care including microbiome-based recommendations. Advocacy organizations and patient networks are influencing treatment adoption by promoting evidence-based care and engaging in policy dialogue. Employer-led wellness programs are slowly gaining traction in parts of Western Europe, offering coverage for menopause therapies and counseling as part of broader gender equity initiatives. Digital integration continues to strengthen, with AI-enabled symptom monitoring tools and multilingual mobile platforms improving patient engagement and physician follow-up.

Market Drivers

• Strong Healthcare Systems and Coverage: Europe’s public healthcare systems cover menopause treatments broadly. For example, the UK’s National Health Service (NHS) offers hormone replacement therapy (HRT) with costs largely subsidized. Countries like Germany and France also provide reimbursement for menopause-related care, reducing financial barriers for women. According to the European Menopause and Andropause Society (EMAS), this strong healthcare support results in higher treatment uptake compared to regions with less coverage. The accessibility encourages women to seek timely diagnosis and care, driving market growth across urban and rural areas.
• Growing Awareness and Medical Education: EMAS reports that menopause education has improved significantly in Europe, with 85% of gynecologists receiving formal menopause training as of 2023. Public campaigns in countries like Spain and Italy increase knowledge about menopause symptoms and risks. This rise in awareness reduces stigma and encourages women to consult healthcare providers, boosting demand for both hormonal and non-hormonal therapies. Surveys show that over 70% of European women feel better informed about menopause compared to a decade ago.

Market Challenges

• Variations in Treatment Acceptance: According to EMAS data, HRT usage in Europe varies between 15% in Eastern European countries to over 30% in Northern Europe. Concerns about cancer risk and side effects continue to cause hesitation among women, despite updated WHO and EMAS guidelines recommending safe, personalized use. Cultural attitudes also differ; for instance, skepticism remains higher in Poland and Hungary compared to Sweden or the Netherlands, leading to uneven market penetration of hormone therapies.
• Ageing Population and Comorbidities: Europe has one of the oldest populations worldwide, with over 20% of women above 60 years. Many experience multiple chronic diseases like diabetes and cardiovascular issues that complicate menopause treatment. Physicians often balance menopause symptom relief against risks of hormone therapy in these cases. This complexity slows treatment initiation and limits therapy options, impacting market growth.

Market Trends

• Personalized Hormone Therapy Approaches: European clinicians increasingly use diagnostic tools to tailor hormone therapy based on individual patient profiles. EMAS guidelines (2025) promote personalized regimens adjusting hormone type and dosage to minimize risks. Countries like Germany and France report growing prescription rates for low-dose transdermal patches and bioidentical hormones. This precision medicine approach improves treatment satisfaction and encourages wider adoption of hormone therapies.
• Integration of Digital Health Solutions: Digital health adoption is rising, with apps like “MenoTrack” used by 30% of menopausal women in the UK and Germany (2024 survey). Telemedicine consultations for menopause care have increased by 45% post-pandemic, especially in rural areas with limited specialist access. These platforms provide symptom tracking, education, and remote prescribing, enhancing convenience and patient engagement. The trend aligns with the European Commission’s digital health strategy promoting e-health across member states.

Dietary supplements dominate as the largest and fastest-growing treatment segment in the Europe menopause market because of increasing consumer preference for natural and non-hormonal options to manage menopausal symptoms.

Many women in Europe seek alternatives to hormone replacement therapy due to concerns about side effects and long-term risks. Supplements such as phytoestrogens, vitamins, and herbal extracts are viewed as safer and more holistic approaches, offering relief from hot flashes, mood swings, and bone density loss without the adverse effects associated with hormones. The growing health and wellness trend across European countries fuels demand for plant-based supplements and nutraceuticals. Accessibility through pharmacies, health stores, and online platforms allows women to easily incorporate these supplements into daily routines. Additionally, rising awareness about menopause and its impact on quality of life encourages proactive management using dietary supplements. Regulatory frameworks in Europe support the marketing and sale of high-quality supplements, ensuring safety and efficacy, which builds consumer confidence. Public health campaigns and education by NGOs also highlight the benefits of natural therapies, increasing adoption rates. The aging population and the longer postmenopausal phase experienced by European women contribute to sustained demand for long-term symptom management solutions that dietary supplements provide. Furthermore, personalized nutrition trends and digital health platforms help women choose supplements tailored to their specific symptoms. Collaboration between supplement manufacturers and healthcare professionals enhances trust and expands market reach. The convenience of combining multiple benefits in one supplement product appeals to time-conscious consumers seeking effective menopause relief.

Menopause is the largest and fastest stage segment in the Europe menopause market because it marks the definitive cessation of menstruation and is often when women most actively seek treatment to manage symptoms.

The global definition, which is 12 consecutive months without menstruation typically between ages 45 and 55, applies strongly across Europe, where women are well-informed and supported by healthcare systems during this stage. Menopause triggers noticeable symptoms such as hot flashes, night sweats, and mood disturbances, prompting a surge in healthcare consultations and treatment initiation during this period. Women in Europe tend to have better access to specialists and therapies during menopause, supported by national health services and insurance reimbursement policies, encouraging timely intervention. The postmenopausal stage, while important, often involves long-term health monitoring rather than active symptom management, making the menopause stage more critical for therapeutic demand. Cultural acceptance and awareness campaigns help reduce stigma, motivating women to seek help during this stage rather than delaying treatment. Advances in clinical guidelines and personalized medicine also focus on this stage for optimizing hormone replacement and alternative therapies, leading to increased healthcare utilization. Additionally, increasing digital health tools provide women with better symptom tracking and management options. Research efforts continue to identify stage-specific treatments, further emphasizing menopause as the key phase for intervention. The growing support groups and community initiatives enhance patient engagement during this transitional period. The availability of specialized menopause clinics across Europe further improves patient outcomes by offering focused care. Moreover, ongoing education for healthcare providers ensures updated treatment approaches are consistently applied.

Oral administration remains the largest route of administration in the Europe menopause market because it is well-established, convenient, and widely accepted by both patients and healthcare providers for delivering hormone replacement therapy and other treatments.

Many women and clinicians favor oral therapies due to their familiarity, ease of use, and availability in various formulations like tablets and capsules. Oral hormone replacement therapy (HRT) has been extensively studied and used for decades in Europe, with healthcare systems and insurance plans supporting its prescription and reimbursement. This long history has built a strong trust in oral delivery methods despite the rise of alternative routes such as transdermal patches or gels. Oral medications are also easier to manufacture and distribute, making them widely accessible across different European countries and healthcare settings. Additionally, dosing with oral pills is straightforward, which appeals to many women managing their symptoms independently without frequent clinical visits. European clinical guidelines continue to recommend oral HRT as a standard option, especially for younger menopausal women without contraindications. Furthermore, oral therapies can address systemic symptoms effectively, which increases their preference among doctors and patients. The cost-effectiveness of oral drugs compared to newer or more complex delivery systems also contributes to their dominance. Despite some concerns regarding first-pass liver metabolism and side effects, the convenience and widespread acceptance keep oral administration as the primary mode for menopause treatment across Europe. Ongoing research and improved formulations also work to minimize risks associated with oral therapies, enhancing their safety profile. This continued innovation helps maintain oral treatments as the leading choice in Europe’s menopause market.

Hospitals serve as the largest end user in the Europe menopause market because they provide comprehensive and multidisciplinary care essential for managing the complex health needs of menopausal women.

Hospitals bring together specialists such as gynecologists, endocrinologists, and general practitioners who collaborate closely to diagnose and treat menopausal symptoms along with associated health risks like osteoporosis and cardiovascular disease. The availability of advanced diagnostic tools such as hormone level assays, bone density scans, and cardiovascular screenings within hospital settings allows for thorough patient evaluation and personalized treatment planning. Women with moderate to severe menopausal symptoms often prefer hospitals for their ability to offer integrated care, including prescription therapies, counseling, and monitoring of treatment outcomes. In addition, hospitals often participate in clinical trials and early adoption of new menopause therapies, attracting patients seeking the latest options. Insurance policies in many European countries favor hospital-based care by covering a significant portion of treatment costs, making hospitals more accessible and affordable. Public health initiatives and awareness campaigns frequently use hospitals as central hubs for menopause education and screening, driving patient inflow. The trust in hospital care for managing menopausal health is also reinforced by well-established referral systems from primary care providers. This network facilitates timely specialist consultations and follow-ups in hospital environments. As menopause often intersects with other chronic conditions common in aging European populations, hospitals are well-equipped to manage multiple comorbidities simultaneously, improving patient outcomes.

Retail pharmacy is the largest distribution channel in the Europe menopause market because it offers widespread accessibility, convenience, and trusted direct interaction with healthcare products, making it the preferred choice for many women managing menopausal symptoms.

Across Europe, retail pharmacies are embedded in both urban and rural communities, providing easy and immediate access to a wide range of menopause treatments including hormonal therapies, non-hormonal options, and dietary supplements. Many women prefer visiting retail pharmacies because they can receive professional advice from pharmacists, who often act as the first point of contact in healthcare. This direct engagement allows patients to ask questions, get guidance on medication use, and clarify side effects, which supports better treatment adherence and confidence in their choices. Moreover, retail pharmacies operate extended hours and do not require appointments, offering flexible access that suits busy lifestyles. The integration of pharmacies into national healthcare systems in many European countries also means that treatments dispensed through these channels are frequently covered by insurance or government reimbursement, reducing out-of-pocket costs for patients. Retail pharmacies also serve as convenient pick-up points for prescription and over-the-counter menopause products, supporting both regular and emergency needs. With growing awareness and education on menopause, more women seek discreet yet accessible sources for their treatment, and retail pharmacies meet this demand effectively. They also provide an environment where women can obtain complementary products like vitamins and natural supplements alongside prescription medications, enabling a holistic approach to symptom management. The trust built between pharmacists and customers over time reinforces the role of retail pharmacies as a reliable and consistent distribution channel.

Germany leads the European menopause market mainly due to its well-established healthcare system, strong emphasis on medical research, and comprehensive insurance coverage that supports widespread access to menopause treatments.

Germany’s leadership in the European menopause market comes from a combination of a robust healthcare infrastructure and a culture that prioritizes preventive care and women’s health. The country’s universal health insurance system ensures that a large majority of women have access to a variety of menopause-related therapies, including hormone replacement therapy and non-hormonal treatment options. This broad coverage reduces financial barriers, making treatment more accessible to women across different socioeconomic groups. German healthcare providers, including gynecologists and general practitioners, are well-trained in menopause management, which results in timely diagnosis and personalized care plans tailored to individual needs. The country also invests heavily in medical research, with numerous clinical trials and studies focused on developing safer and more effective menopause treatments, positioning Germany at the forefront of innovation in this space. Public health campaigns and educational initiatives raise awareness about menopause symptoms and risks, encouraging women to seek professional advice early on. Additionally, Germany’s pharmaceutical industry plays a crucial role by producing advanced therapies and working closely with healthcare providers to ensure that new products are quickly adopted. The integration of digital health technologies, such as telemedicine and symptom tracking apps, further enhances access to care, especially for women living in rural areas. Cultural attitudes in Germany support open conversations about menopause, helping to reduce stigma and foster a proactive approach to managing this life stage. The collaboration between healthcare providers, insurers, researchers, and advocacy groups creates a comprehensive ecosystem that effectively meets the needs of menopausal women.

***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation. Show more